FDA Speeds Up Process for Two More Experimental Alzheimer’s Drugs: Donanemab, Lecanemab

This week, on the heels of Aduhelm’s FDA approval, the agency granted breakthrough status to two more prospective new Alzheimer’s treatments, Eli Lilly &…